Drug-Related Side Effects and Adverse Reactions
"Drug-Related Side Effects and Adverse Reactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Descriptor ID |
D064420
|
| MeSH Number(s) |
C25.100
|
| Concept/Terms |
Drug-Related Side Effects and Adverse Reactions- Drug-Related Side Effects and Adverse Reactions
- Drug Related Side Effects and Adverse Reactions
- Side Effects of Drugs
- Drug Side Effects
- Drug Side Effect
- Effects, Drug Side
- Side Effect, Drug
- Side Effects, Drug
- Adverse Drug Reaction
- Adverse Drug Reactions
- Drug Reaction, Adverse
- Drug Reactions, Adverse
- Reactions, Adverse Drug
- Adverse Drug Event
- Adverse Drug Events
- Drug Event, Adverse
- Drug Events, Adverse
Drug Toxicity- Drug Toxicity
- Toxicity, Drug
- Drug Toxicities
- Toxicities, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug-Related Side Effects and Adverse Reactions".
Below are MeSH descriptors whose meaning is more specific than "Drug-Related Side Effects and Adverse Reactions".
This graph shows the total number of publications written about "Drug-Related Side Effects and Adverse Reactions" by people in this website by year, and whether "Drug-Related Side Effects and Adverse Reactions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 4 | 1 | 5 |
| 2000 | 3 | 0 | 3 |
| 2001 | 3 | 1 | 4 |
| 2002 | 1 | 0 | 1 |
| 2003 | 5 | 1 | 6 |
| 2004 | 4 | 2 | 6 |
| 2005 | 1 | 3 | 4 |
| 2006 | 5 | 3 | 8 |
| 2007 | 6 | 2 | 8 |
| 2008 | 1 | 6 | 7 |
| 2009 | 3 | 4 | 7 |
| 2010 | 2 | 9 | 11 |
| 2011 | 3 | 6 | 9 |
| 2012 | 6 | 3 | 9 |
| 2013 | 10 | 2 | 12 |
| 2014 | 6 | 2 | 8 |
| 2015 | 7 | 3 | 10 |
| 2016 | 14 | 6 | 20 |
| 2017 | 6 | 5 | 11 |
| 2018 | 9 | 2 | 11 |
| 2019 | 8 | 7 | 15 |
| 2020 | 5 | 4 | 9 |
| 2021 | 4 | 2 | 6 |
| 2022 | 11 | 0 | 11 |
| 2023 | 8 | 2 | 10 |
| 2024 | 4 | 0 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug-Related Side Effects and Adverse Reactions" by people in Profiles.
-
Frequency and preventability of adverse drug events in the outpatient setting. BMJ Qual Saf. 2025 Jul 18; 34(8):499-506.
-
Adverse Drug Events in Ambulatory Care: A Cross-Sectional Study. Drug Saf. 2025 Apr; 48(4):363-374.
-
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE?). Qual Life Res. 2025 Feb; 34(2):495-507.
-
Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE?) in a diverse cancer sample. Clin Trials. 2025 Apr; 22(2):161-169.
-
Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract. 2025 Sep; 21(9):1265-1273.
-
Outpatient Laboratory Monitoring for Antibiotic-related Adverse Events in Children With Acute Hematogenous Osteomyelitis. Pediatr Infect Dis J. 2025 Mar 01; 44(3):e74-e76.
-
Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol. 2024; 15:1447021.
-
Association of Pharmacist Interventions With Adverse Drug Events and Potential Adverse Drug Events. Pharmacoepidemiol Drug Saf. 2024 07; 33(7):e5853.
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399.
-
Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw. 2024 01 08; 22(5).